[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 3 sources · 6 days · First seen · Last updated

European biotechnology innovation and funding gaps

Overview

The European and DACH (Germany, Austria, and Switzerland) biotechnology sectors are facing significant structural challenges regarding innovation, talent, and capital. Reports indicate a critical gap in the ability to translate scientific discoveries into commercially viable companies, often referred to as ‘Valleys of Death’.

While the region maintains high academic and R&D standards, it struggles to scale compared to North America and China. A primary concern is the massive funding gap; European venture capital accounts for approximately 7 percent of the global life sciences market, whereas US-based funds hold 63 percent. Industry leaders have emphasized the necessity of long-term capital to support companies moving from research toward international expansion.

Specific corporate setbacks have also been noted, such as BioNTech ending a Phase 2 oncology study due to a numerical imbalance in overall survival, alongside declining revenues and revised sales forecasts.

Entities

Carma Fund · European Investment Bank · Biotech Summit Austria · Karl Nehammer · Brandenburg Kapital

Timeline

  1. [BUSINESS] 2 sources
    DACH region life sciences sector faces translation and funding gaps

    Industry leaders highlight the need to bridge the gap between scientific research and commercial success in the DACH region's life sciences sector to compete with North America and China.

  2. [BUSINESS] 2 sources
    European biotechnology sector faces structural funding and innovation gaps

    A report by ESMT Berlin warns of a critical structural deficit in Europe's biotech sector, citing funding gaps and poor technology transfer, as companies like BioNTech face clinical and financial transitions.

Sources

bionity.com · kapitalmarktexperten.de · vc-magazin.de